Non-transferrin-bound iron in the serum of hemodialysis patients who receive ferric saccharate: No correlation to peroxide generation

Journal of the American Society of Nephrology

Volumn 15, Issue 6, 2004, Pages 1648-1655

  Scheiber Mojdehkar, Barbara ^a   Lutzky, Barbara ^a   Schaufler, Roland ^b   Sturm, Brigitte ^a   Goldenberg, Hans ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b WILHELMINEN HOSPITAL   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

C REACTIVE PROTEIN; CALCEIN; FERRIC HYDROXIDE SUCROSE; FERRITIN; IRON; IRON SACCHARATE; PEROXIDE; TRANSFERRIN; UREA;

ANEMIA; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; ENZYME IMMUNOASSAY; HEMODIALYSIS; HUMAN; HUMAN CELL; KIDNEY FAILURE; OXIDATIVE STRESS; POLYACRYLAMIDE GEL ELECTROPHORESIS; PRIORITY JOURNAL; SERUM; TURBIDIMETRY; WESTERN BLOTTING;

EID: 2542445349     PISSN: 10466673     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.ASN.0000130149.18412.56     Document Type: Article

References (50)

1. McGonigle RW, Wallin JD, Shadduck RK, Fisher JW: Erythropoietin deficiency and inhibition of erythropoiesis in renal insufficiency. Kidney Int 25: 437-444, 1984
2. Eschbach JW, Kelly MR, Haley NR: Treatment of anemia of progressive renal failure with recombinant human erythropoietin. N Engl J Med 321: 158-163, 1989
3. Sunder-Plassmann G, Hörl WH: Importance of iron supply for erythropoietin therapy. Nephrol Dial Transplant 10: 2070-2076, 1995
4. Hörl WH: Consensus statement. How to diagnose and correct iron deficiency during rHuEpo therapy: A consensus report. Nephrol Dial Transplant 11: 246-250, 1996
5. Fishbane S, Imbriano LJ, Kowalski EA, Maesaka JK: The evaluation of iron status in hemodialysis patients. J Am Soc Nephrol 7: 2654-2657, 1996
6. Nissenson AR, Strobos J: Iron deficiency in patients with renal failure. Kidney Int 69S: 107-118, 1999
7. Sunder-Plassmann G, Horl WH: Safety aspects of parenteral iron in patients with end-stage renal disease. Drug Saf 17: 241-250, 1997
8. Fishbane S, Kowalski EA: The comparative safety of intravenous iron dextran, iron saccharate, and sodium ferric gluconate. Semin Dial 13: 381-384, 2000
9. Chandler G, Harchoval J, McDougall IC: Intravenous iron sucrose: Establishing a safe dose. Am J Kidney Dis 38: 988-991, 2001
10. Banyai S, Rainer V, Derfler K, Druml W, Hörl W, Sunder-Plassmann G: Bleomycin-detectable free iron (BDI) is present in patients on intravenous (IV) iron therapy [Abstract]. J Am Soc Nephrol 9: 199, 1998:
11. Parkkinen J, von Bonsdorff L, Peltonen S, Gronhagen-Riska C, Rosenlof K: Catalytically active iron and bacterial growth in serum of hemodialysis patients after i.v. iron saccharate administration. Nephrol Dial Transplant 15: 1827-1834, 2000
12. Breuer W, Ronson A, Slotki IN, Abramov A, Hershko C, Cabantchik ZI: The assessment of serum nontransferrin-bound iron in chelation therapy and iron supplementation. Blood 95: 2975-2982, 2000
13. Esposito BP, Breuer W, Slotki I, Cabantchik ZI: Labile iron in parenteral iron formulations and its potential for generating plasma nontransferrin-bound iron in dialysis patients. Eur J Clin Invest 32S: 42-49, 2002
14. Kooistzra MP, Kersting S, Gosriwatana I, Lu S, Nijhoff-Schutte J, Hider RC, Marx JJM: Nontransferrin-bound iron in the plasma of hemodialysis patients after intravenous iron saccharate infusion. Eur J Clin Invest 32S: 36-41, 2002
15. Roob JM, Khoschsorur G, Tiran A, Horina JH, Holzer H, Winklhofer-Roob BM: Vitamin E attenuates oxidative stress induced by intravenous iron in patients on hemodialysis. J Am Soc Nephrol 11: 539-549, 2000
16. Herrera J, Nava M, Romero F, Rodriguez-Iturbe B: Melatonin prevents oxidative stress resulting from iron and erythropoietin administration. Am J Kidney Dis 37: 750-757, 2001
17. Lim P-S, Wei Y-H, Yu YL, Kho B: Enhanced oxidative stress in hemodialysis patients receiving intravenous iron therapy. Nephrol Dial Transplant 14: 2680-2687, 1999
18. Cavdar C, Temiz A, Yenicerioglu Y, Caliskn S, Celik A, Sifil A, Onvural B, Camsari T: The effects of intravenous iron treatment on oxidant stress and erythrocyte deformability in hemodialysis patients. Scand J Urol Nephrol 37: 77-82, 2003
19. Patruta SI, Edlinger R, Sunder-Plassmann G, Hörl WH: Neutrophil impairment associated with iron therapy in hemodialysis patients with functional iron deficiency. J Am Soc Nephrol 9: 655-663, 1998
20. Collins A, Ebben J, Ma J: Frequent IV iron dosing is associated with higher infectious deaths [Abstract]. J Am Soc Nephrol 8: 190, 1997
21. Canziani ME, Yumiya ST, Rangel EB, Manfredi SR, Neto MC, Draibe SA: Risk of bacterial infection in patients under intravenous iron therapy: Dose versus length of treatment. Artif Organs 25: 866-869, 2001
22. Locatelli F, Canaud B, Eckardt KU, Stenvinkel P, Wanner C, Zoccali C: Oxidative stress in end-stage renal disease: an emerging threat to patient outcome. Nephrol Dial Transplant 18: 1272-1280, 2003
23. Halliwell G, Gutteridge JM: Role of free radicals and catalytic metal ions in human disease: An overview. Methods Enzymol 186: 1-85, 1990
24. Gutteridge LM, Halliwell B: Free radicals and antioxidants in the year 2000. A historical look to the future. Ann N Y Acad Sci 899: 136-147, 2000
25. Hider RC: Nature of nontransferrin-bound iron. Eur J Clin Invest 32S: 50-54, 2002
26. Grootveld M, Bell JD, Halliwell B, Aruoma OI, Bromford A, Sadler PJ: Non-transferrin-bound iron in plasma or serum from patients from patients with idiopathic hemochromatosis. J Biol Chem 264: 4417-4422, 1989
27. Hershko CA, Graham G, Bates GW, Rachmilewitz EA: Non-specific serum iron in thalassaemia: An abnormal serum iron fraction of potential toxicity. Br J Haematol 40: 255-263, 1978
28. Grootveld M, Bell JD, Halliwell B, Aruoma OJ, Bomford A, Sadler PJ: Non-transferrin-bound iron in plasma or serum from patients with idiopathic hemochromatosis: Characterization by high performance liquid chromatography and nuclear magnetic resonance spectroscopy. J Biol Chem 264: 4417-4422, 1989
29. Breuer W, Hershko C, Cabantchik ZI: The importance of non-transferrin bound iron in disorders of iron metabolism. Transfus Sci 23: 185-192, 2000
30. Seligman PA, Schleicher RB: Comparison of methods used to measure serum iron in the presence of iron gluconate or iron dextran. Clin Chem 45: 898-901, 1999
31. Besarab A: Parenteral iron therapy: Safety and efficacy. Semin Dial 12: 237-242, 1999
32. Scheiber-Mojdehkar B, Sturm B, Plank L, Kryzer I, Goldenberg H: Influence of parenteral iron preparations on non-transferrin bound iron uptake, the iron regulatory protein and the expression of ferritin and the divalent metal transporter DMT-1 in HepG2 human hepatoma cells. Biochem Pharmacol 65: 1973-1978, 2003
33. Sturm B, Goldenberg H, Scheiber-Mojdehkar B: Transient increase of the labile iron pool in HepG2 cells by intravenous iron preparations. Eur J Biochem 270: 3731-3738, 2003
34. Rothman RJ, Serroni A, Farber JL: Cellular pool of transient ferric iron, chelatable by deferoxamine and distinct from ferritin, that is involved in oxidative cell injury. Mol Pharmacol 42: 703-710, 1992
35. Kirschbaum B: Hypotransferrinemia of chronically hemodialyzed patients. Artif Organs 23: 1047-1054, 1999
36. Geisser P, Baer M, Schaub E: Structure/histotoxicity relations of parenteral iron. Drug Res 42: 1439-1452, 1992
37. Danielson BG, Salmonson T, Derendorf H, Geisser P: Pharmacokinetics of Iron(III)-sucrose complex after a single intravenous dose in healthy volunteers. Drug Res 46: 615-621, 1996
38. Sunder-Plassmann G, Hoerl WH: Safety of intravenous injection of iron saccharate in haemodialysis patients. Nephrol Dial Transplant 11: 1797-1802, 1996
39. Gutteridge JMC, Rowley DA, Halliwell B: Superoxide-dependent formation of hydroxyl radicals in the presence of iron salts. Biochem J 199: 263-265, 1981
40. Evans PJ, Halliwell B: Measurement of iron and copper in biological systems: Bleomycin and copper-phenantroline assays. Methods Enzymol 233: 82-92, 1994
41. Esposito BP, Breuer W, Sirankapracha P, Pootrakul P, Hershko C, Cabantchik ZI: Labile plasma iron in iron overload: Redox activity and susceptibility to chelation. Blood 102: 2670-2677, 2003
42. Singh S, Hider RC, Porter JB: A direct method for quantification of non-transferrin-bound iron. Anal Biochem 186: 320-323, 1990
43. Esposito BP, Epsztejn S, Breuer W, Cabantchik ZI: A review of fluorescence methods for assessing labile iron in cells and biological fluids. Anal Biochem 304: 1-18, 2002
44. Gosriwatana I, Loreal O, Lu S, Brissot P, Porter JB, Hider RC: Quantification of non-transferrin-bound iron in the presence of unsaturated transferrin. Anal Biochem 273: 212-220, 1999
45. Makey DG, Seal US. The detection of four molecular forms of human transferrin during the iron binding process. Biochim Biophys Acta 453: 250-256, 1976
46. Pollack S, Vanderhoff G, Lasky F: Iron removal from transferrin. An experimental study. Biochim Biophys Acta 497: 481-487, 1977
47. Baldwin DA: The kinetics of iron release from human transferrin by EDTA. Effect of salts and detergents. Biochim Biophys Acta 623: 183-198, 1980
48. Plekhanov AY: Immunoreplica from the gel surface: Rapid and sensitive blot plus intact gel. Anal Biochem 239: 110-111, 1996
49. Breuer W, Epsztejn S, Cabantchik ZI: Iron acquired from transferrin by K562 cells is delivered into a cytoplasmic pool of chelatable iron. J Biol Chem 270: 24209-24215, 1995
50. Zanen AL, Adriaansen HJ, Bommel EHF, Posthuma R, de Jong GMTh: "Oversaturation" of transferrin after intravenous ferric gluconate (Ferrlecit®) in hemodialysis patients. Nephrol Dial Transplant 11: 820-824, 1996